TherapeuticsMD, Inc. (TXMD): Price and Financial Metrics

TherapeuticsMD, Inc. (TXMD): $4.58

-0.22 (-4.58%)

POWR Rating

Component Grades














  • TXMD scores best on the Value dimension, with a Value rank ahead of 85.52% of US stocks.
  • TXMD's strongest trending metric is Value; it's been moving up over the last 179 days.
  • TXMD ranks lowest in Stability; there it ranks in the 12th percentile.

TXMD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for TXMD is -1.81 -- better than only 4.34% of US stocks.
  • In terms of volatility of its share price, TXMD is more volatile than 96.97% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TXMD comes in at 304.42% -- higher than that of 99% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to THERAPEUTICSMD INC are MTG, BWEN, AMS, CLW, and OTLY.
  • Visit TXMD's SEC page to see the company's official filings. To visit the company's web site, go to

TXMD Valuation Summary

  • In comparison to the median Healthcare stock, TXMD's price/earnings ratio is 121.12% lower, now standing at -4.9.
  • Over the past 130 months, TXMD's price/sales ratio has gone down 100.4.

Below are key valuation metrics over time for TXMD.

Stock Date P/S P/B P/E EV/EBIT
TXMD 2022-11-25 0.5 -0.9 -4.9 3.5
TXMD 2022-11-23 0.5 -0.8 -4.6 3.4
TXMD 2022-11-22 0.5 -0.9 -4.9 3.5
TXMD 2022-11-21 0.5 -0.9 -5.0 3.5
TXMD 2022-11-18 0.5 -1.0 -5.5 3.7
TXMD 2022-11-17 0.6 -1.0 -5.8 3.8

TXMD Growth Metrics

    Its 2 year price growth rate is now at -95.09%.
  • The 4 year price growth rate now stands at -79.62%.
  • The 5 year net income to common stockholders growth rate now stands at -115.28%.
Over the past 52 months, TXMD's revenue has gone up $71,410,782.

The table below shows TXMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 87.489 -103.408 -8.665
2022-06-30 91.978 -122.711 -27.12
2022-03-31 86.418 -133.839 -182.053
2021-12-31 86.951 -142.693 -172.415
2021-09-30 90.85079 -133.4563 -171.5426
2021-06-30 84.78759 -129.282 -156.7337

TXMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TXMD has a Quality Grade of D, ranking ahead of 19.35% of graded US stocks.
  • TXMD's asset turnover comes in at 0.419 -- ranking 109th of 682 Pharmaceutical Products stocks.
  • ALNY, QGEN, and CASI are the stocks whose asset turnover ratios are most correlated with TXMD.

The table below shows TXMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.419 0.791 -0.569
2021-03-31 0.361 0.752 -0.564
2020-12-31 0.311 0.754 -0.620
2020-09-30 0.254 0.772 -0.681
2020-06-30 0.253 0.817 -0.738
2020-03-31 0.225 0.857 -0.822

TXMD Price Target

For more insight on analysts targets of TXMD, see our TXMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.80 Average Broker Recommendation 1.38 (Strong Buy)

TXMD Stock Price Chart Interactive Chart >

Price chart for TXMD

TXMD Price/Volume Stats

Current price $4.58 52-week high $30.50
Prev. close $4.80 52-week low $1.99
Day low $4.45 Volume 139,500
Day high $4.87 Avg. volume 514,907
50-day MA $5.98 Dividend yield N/A
200-day MA $9.26 Market Cap 43.17M

TherapeuticsMD, Inc. (TXMD) Company Bio

TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company was founded in 2008 and is based in Boca Raton, Florida.

TXMD Latest News Stream

Event/Time News Detail
Loading, please wait...

TXMD Latest Social Stream

Loading social stream, please wait...

View Full TXMD Social Stream

Latest TXMD News From Around the Web

Below are the latest news stories about THERAPEUTICSMD INC that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 15, 2022

TherapeuticsMD Announces Third Quarter 2022 Financial Results

BOCA RATON, Fla., November 14, 2022--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.

Yahoo | November 14, 2022

TherapeuticsMD raises additional $7M in private investment (NASDAQ:TXMD)

TherapeuticsMD (TXMD) has received an additional $7M private investment in the company’s Series A Preferred Stock from Rubric Capital Management.The additional funds will be used…

Seeking Alpha | October 31, 2022

TherapeuticsMD Announces Additional $7 Million Private Placement

BOCA RATON, Fla., October 31, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women’s healthcare company, announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital.

Yahoo | October 31, 2022

TherapeuticsMD Announces $7 Million Private Placement

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received a $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company’s financing agreement with its lender, Sixth Street Specialty Lending,

Business Wire | October 3, 2022

Read More 'TXMD' Stories Here

TXMD Price Returns

1-mo -22.77%
3-mo -55.01%
6-mo -53.88%
1-year -79.97%
3-year -96.21%
5-year -98.52%
YTD -74.23%
2021 -70.62%
2020 -50.00%
2019 -36.48%
2018 -36.92%
2017 4.68%

Continue Researching TXMD

Here are a few links from around the web to help you further your research on TherapeuticsMD Inc's stock as an investment opportunity:

TherapeuticsMD Inc (TXMD) Stock Price | Nasdaq
TherapeuticsMD Inc (TXMD) Stock Quote, History and News - Yahoo Finance
TherapeuticsMD Inc (TXMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7617 seconds.